China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor

March 1, 2010

SHANGHAI, March 1 /PRNewswire-Asia-FirstCall/ — China-Biotics, Inc.
(“China-Biotics,” “the Company”) (Nasdaq: CHBT), the leading developer,
manufacturer and distributor of probiotics products in China, today announced
that that it has appointed Grayling to develop and implement a comprehensive
communications program to strategically position and raise the visibility of
the Company’s growth story, and explain its financial performance to
shareholders, potential investors and the financial media.

Jinan Song, Chairman and Chief Executive Officer of China-Biotics,
commented, “As China-Biotics is upgrading its production capabilities and
expanding its customer portfolio, we are pleased to have Grayling help us
create greater global awareness of our competitive advantages and strong
growth prospects in the expanding probiotics market.”

Grayling, a subsidiary of Huntsworth plc (LSE: HNT), is headquartered in
London, and it has merged with sister companies Trimedia and Mmd to create a
new global Investor Relations, Public Relations, Public Affairs and Events
consultancy. The new company has a global footprint with offices in 70
locations in 40 countries across Europe, the US, the Middle East and Asia
. Grayling is the second largest independent PR firm in the world.
http://www.grayling.com .

About China-Biotics

China-Biotics, Inc. (“China-Biotics,” “the Company”), a leading
manufacturer of biotechnology products and supplements, engages in the
research, development, marketing and distribution of probiotics dietary
supplements in China. Through its wholly owned subsidiary, Shanghai Shining
Biotechnology Co., Ltd., the Company develops and produces its proprietary
product portfolio including live microbial nutritional supplements under the
“Shining” brand. Currently, the products are sold OTC through large
distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang
province. In February 2010, China-Biotics began its commercial production in
China’s largest probiotics production facility to meet growing demand in China.
For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement

The information in this release contains forward-looking statements which
involve risks and uncertainties, including statements regarding the Company’s
capital needs, business strategy and expectations. Any statements contained
herein that are not statements of historical fact may be deemed to be
forward-looking statements, which may be identified by terminology such as
“may,” “should,” “will,” “expect,” “plan,” “intend,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “forecast,” “project,” or “continue,” the
negative of such terms or other comparable terminology. Readers should not
rely on forward-looking statements as predictions of future events or results.
Any or all of the Company’s forward-looking statements may turn out to be
wrong. They can be affected by inaccurate assumptions, risks and uncertainties
and other factors which could cause actual events or results to be materially
different from those expressed or implied in the forward-looking statements.
In evaluating these statements, readers should consider various factors,
including the risks described in “Item 1A. Risk Factors” beginning on page 15
and elsewhere in the Company’s 2009 Annual Report on Form 10-K. These factors
may cause the Company’s actual results to differ materially from any
forward-looking statement. In addition, new factors emerge from time to time
and it is not possible for the Company to predict all factors that may cause
actual results to differ materially from those contained in any forward-
looking statements. The Company disclaims any obligation to publicly update
any forward-looking statements to reflect events or circumstances after the
date of this document, except as required by applicable law.

    For more information, please contact:

     Travis Cai
     Chief Financial Officer
     China-Biotics, Inc.
     Email: traviscai@chn-biotics.com

     Kevin Theiss
     Tel:   +1-646-284-9409
     Email: kevin.theiss@grayling.com

SOURCE China-Biotics, Inc.

Source: newswire

comments powered by Disqus